A Neuroleptic malignant syndrome patient associated with COVID-19: Case report
- Journal of Neurology & Stroke
PDF Full Text
- Introduction:Various neurological manifestations associated with COVID-19 have been detected, and its incidence has been increasing. Neurological symptoms in COVID-19 patients have been determined by 36.4% and were common with severe infection. In literature, neuroleptic malignant syndrome relevant to patients with COVID-19 has been reported very few.
- Case:A 72-year-old man was admitted to our clinic with an altered mental status, speech disorder, occasionally urinary incontinence. His tremors, diaphoresis, tachycardia, and fever had been developed 3 days before admission. In the neurologic examination, the patient was disoriented and confused, and he had a lead pipe posture. The cerebral magnetic resonance imaging (MRI) and diffusion-weighted MRI was normal. The creatinine kinase (CK) was increased. The diagnosis of the neuroleptic malignant syndrome (NMS) has been confirmed based on DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition), Nierenberg, and Levenson criteria. Non-enhanced chest computed tomography (CT) has shown the COVID-19 infiltration. COVID-19 test by PCR (Polymerase Chain Reaction) was positive in the nasopharyngeal swab. After bromocriptine and intravenous hydration treatment, his CK began to downtrend on day 3, and rigidity also improved.
- Conclusion:In our case first reported in Turkey, the neuroleptic malignant syndromer are in patients with COVID-19 has been determined. It aimed to raise awareness on this subject.
neuroleptic malignant syndrome, COVID-19, pandemic